| Title | Population Analyses of Atorvastatin Clearance in Patients Living in the Community and in Nursing Homes. | | Author(s) | Schwartz JB, Verotta D | | Institution | [1] Division of Clinical Pharmacology, University of California, San Francisco, San Francisco, California, USA [2] Department of Medicine, University of California, San Francisco, San Francisco, California, USA [3] Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California, USA [4] Department of Research, The Jewish Home of San Francisco, San Francisco, California, USA. | | Source | Clin Pharmacol Ther 2009 Jul 1. | | Abstract | The effects of demographic and clinical covariates on the apparent clearance (CL/F) of orally administered atorvastatin, with chronic dosing in a patient population that included the elderly, were studied in 143 patients (atorvastatin: 34 +/- 26 mg/day, mean +/- SD; men (n = 64), age 64.6 +/- 12.1 years, and women (n = 79), age 69.3 +/- 13 years). The time of dose administration had a strong influence on Ka (faster with morning dosing); the factors found to slow CL/F were coadministration of CYP3A inhibitors and advancing age-the latter factor was relevant only in the men, not in the women.Clinical Pharmacology & Therapeutics (2009); advance online publication 1 July 2009. doi:10.1038/clpt.2009.100. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19571802 |
|
